GRI Bio (GRI) Competitors $1.39 -0.05 (-3.47%) As of 08/15/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GRI vs. ERNA, TXMD, BFRG, CSCI, CARM, IMCC, FLGC, GOVX, PHIO, and PHXMShould you be buying GRI Bio stock or one of its competitors? The main competitors of GRI Bio include Ernexa Therapeutics (ERNA), TherapeuticsMD (TXMD), Bullfrog AI (BFRG), COSCIENS Biopharma (CSCI), Carisma Therapeutics (CARM), IM Cannabis (IMCC), Flora Growth (FLGC), GeoVax Labs (GOVX), Phio Pharmaceuticals (PHIO), and PHAXIAM Therapeutics (PHXM). These companies are all part of the "pharmaceutical products" industry. GRI Bio vs. Its Competitors Ernexa Therapeutics TherapeuticsMD Bullfrog AI COSCIENS Biopharma Carisma Therapeutics IM Cannabis Flora Growth GeoVax Labs Phio Pharmaceuticals PHAXIAM Therapeutics Ernexa Therapeutics (NASDAQ:ERNA) and GRI Bio (NASDAQ:GRI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, media sentiment, analyst recommendations, risk, dividends and valuation. Do analysts recommend ERNA or GRI? GRI Bio has a consensus target price of $22.00, suggesting a potential upside of 1,482.73%. Given GRI Bio's stronger consensus rating and higher probable upside, analysts plainly believe GRI Bio is more favorable than Ernexa Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ernexa Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00GRI Bio 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders have more ownership in ERNA or GRI? 70.6% of Ernexa Therapeutics shares are held by institutional investors. Comparatively, 34.0% of GRI Bio shares are held by institutional investors. 1.5% of Ernexa Therapeutics shares are held by company insiders. Comparatively, 0.9% of GRI Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more volatility & risk, ERNA or GRI? Ernexa Therapeutics has a beta of 5.42, meaning that its stock price is 442% more volatile than the S&P 500. Comparatively, GRI Bio has a beta of -1.61, meaning that its stock price is 261% less volatile than the S&P 500. Is ERNA or GRI more profitable? GRI Bio has a net margin of 0.00% compared to Ernexa Therapeutics' net margin of -7,652.75%. Ernexa Therapeutics' return on equity of 0.00% beat GRI Bio's return on equity.Company Net Margins Return on Equity Return on Assets Ernexa Therapeutics-7,652.75% N/A -682.08% GRI Bio N/A -337.46%-197.01% Which has preferable earnings and valuation, ERNA or GRI? GRI Bio has lower revenue, but higher earnings than Ernexa Therapeutics. Ernexa Therapeutics is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioErnexa Therapeutics$580K20.96-$44.54M-$8.31-0.19GRI BioN/AN/A-$8.21M-$11.56-0.12 Does the media prefer ERNA or GRI? In the previous week, GRI Bio had 2 more articles in the media than Ernexa Therapeutics. MarketBeat recorded 6 mentions for GRI Bio and 4 mentions for Ernexa Therapeutics. Ernexa Therapeutics' average media sentiment score of 0.65 beat GRI Bio's score of 0.38 indicating that Ernexa Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ernexa Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive GRI Bio 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryGRI Bio beats Ernexa Therapeutics on 8 of the 15 factors compared between the two stocks. Get GRI Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for GRI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRI vs. The Competition Export to ExcelMetricGRI BioMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.60M$3.10B$5.69B$9.81BDividend YieldN/A2.23%3.79%4.07%P/E Ratio-0.1220.8931.0825.11Price / SalesN/A363.22466.03115.16Price / CashN/A42.3037.4059.05Price / Book0.188.659.096.18Net Income-$8.21M-$54.65M$3.26B$265.11M7 Day Performance10.32%6.56%7.31%4.20%1 Month Performance-32.85%7.53%5.43%2.00%1 Year Performance-83.35%13.69%30.60%23.76% GRI Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRIGRI Bio2.3546 of 5 stars$1.39-3.5%$22.00+1,482.7%-83.0%$3.60MN/A-0.121News CoverageEarnings ReportShort Interest ↑ERNAErnexa Therapeutics0.6603 of 5 stars$1.67-1.8%N/A-93.9%$12.52M$580K-0.2010News CoverageEarnings ReportShort Interest ↑TXMDTherapeuticsMD0.3935 of 5 stars$1.08+1.8%N/A-27.3%$12.28M$1.76M0.00420Earnings ReportBFRGBullfrog AI1.3845 of 5 stars$1.27flatN/A-56.1%$11.96M$60K-1.574Positive NewsEarnings ReportCSCICOSCIENS BiopharmaN/A$3.59-0.4%N/AN/A$11.31M$9.59M-0.6220News CoverageEarnings ReportGap DownCARMCarisma Therapeutics3.1603 of 5 stars$0.28+2.0%$1.93+598.7%-72.2%$11.28M$19.63M-0.1820Short Interest ↓IMCCIM Cannabis0.949 of 5 stars$2.93+6.9%N/A-12.5%$11.08M$39.44M-4.58340News CoverageEarnings ReportAnalyst DowngradeShort Interest ↓FLGCFlora Growth3.3233 of 5 stars$20.60+9.7%$93.00+351.5%-34.1%$10.84M$59.51M-0.60280Positive NewsShort Interest ↓High Trading VolumeGOVXGeoVax Labs1.8488 of 5 stars$0.68+0.1%$8.88+1,205.5%-77.3%$10.81M$3.95M-0.3410Short Interest ↑PHIOPhio Pharmaceuticals2.5759 of 5 stars$2.13-5.3%$14.00+557.3%-15.5%$10.80MN/A-0.3310News CoverageEarnings ReportAnalyst ForecastShort Interest ↑PHXMPHAXIAM TherapeuticsN/A$3.10flatN/AN/A$10.58MN/A0.0049 Related Companies and Tools Related Companies ERNA Alternatives TXMD Alternatives BFRG Alternatives CSCI Alternatives CARM Alternatives IMCC Alternatives FLGC Alternatives GOVX Alternatives PHIO Alternatives PHXM Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GRI) was last updated on 8/16/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | Sponsored"I'm risking my reputation on this"A massive supply shock is building in the crypto market that could send Bitcoin to $300,000 this year. That...Crypto 101 Media | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GRI Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share GRI Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access